The FDA has approved a new biologic medication for patients with moderate to severe plaque psoriasis. Brodalumab, marketed as Siliq, is indicated for patients who are candidates for systemic therapy or phototherapy and aren’t responding to other systemic therapies.
Because the drug has been linked with suicidal ideation and behavior, including completed suicides, the FDA added a boxed warning to its label. The drug is available only through a restricted program that requires prescribers to register and to counsel patients about the risk. Pharmacies that dispense brodalumab also must register with the program.
Voelker R. Biologic Medication for Psoriasis. JAMA. 2017;317(13):1308. doi:10.1001/jama.2017.2408
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: